Literature DB >> 28926143

Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.

Napat Leeaphorn1, Neetika Garg1, Eliyahu V Khankin1, Francesca Cardarelli1, Martha Pavlakis1.   

Abstract

In the past 20 years, there has been an increase in use of steroid-withdrawal regimens in kidney transplantation. However, steroid withdrawal may be associated with an increased risk of recurrent IgA nephropathy (IgAN). Using United Network of (Organ Sharing/Organ Procurement and Transplantation Network) UNOS/OPTN data, we analyzed adult patients with end-stage renal disease (ESRD) due to IgAN who received their first kidney transplant between 2000 and 2014. For the primary outcome, we used a competing risk analysis to compare the cumulative incidence of graft loss due to IgAN recurrence between early steroid-withdrawal (ESW) and steroid continuation groups. The secondary outcomes were patient survival and death-censored graft survival (DCGS). A total of 9690 recipients were included (2831 in ESW group and 6859 in steroid continuation group). In total, 1238 recipients experienced graft loss, of which 191 (15.43%) were due to IgAN recurrence. In multivariable analysis, steroid use was associated with a decreased risk of recurrence (subdistribution hazard ratio 0.666, 95% CI 0.482-0.921; P = 0.014). Patient survival and DCGS were not different between the two groups. In the USA, ESW in transplant for ESRD due to IgAN is associated with a higher risk of graft loss due to disease recurrence. Future prospective studies are warranted to further address which patients with IgAN would benefit from steroid continuation.
© 2017 Steunstichting ESOT.

Entities:  

Keywords:  IgA nephropathy; immunosuppression; steroids; transplant outcomes

Mesh:

Substances:

Year:  2017        PMID: 28926143      PMCID: PMC5762402          DOI: 10.1111/tri.13075

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  26 in total

Review 1.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

2.  OPTN/SRTR 2013 Annual Data Report: kidney.

Authors:  A J Matas; J M Smith; M A Skeans; B Thompson; S K Gustafson; D E Stewart; W S Cherikh; J L Wainright; G Boyle; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

3.  Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.

Authors:  K C Mange; M M Joffe; H I Feldman
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.

Authors:  J R Von Visger; Y Gunay; K A Andreoni; U Y Bhatt; U S Nori; T E Pesavento; E A Elkhammas; H A Winters; T Nadasdy; N Singh
Journal:  Clin Transplant       Date:  2014-06-24       Impact factor: 2.863

5.  Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era.

Authors:  M Kessler; C Hiesse; D Hestin; D Mayeux; K Boubenider; B Charpentier
Journal:  Am J Kidney Dis       Date:  1996-07       Impact factor: 8.860

6.  Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy.

Authors:  Y S Kim; J I Moon; H J Jeong; M S Kim; S I Kim; K H Choi; H Y Lee; D S Han; K Park
Journal:  Transplantation       Date:  2001-01-27       Impact factor: 4.939

7.  The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival.

Authors:  Gabriella Moroni; Selena Longhi; Silvana Quaglini; Beniamina Gallelli; Giovanni Banfi; Giuseppe Montagnino; Piergiorgio Messa
Journal:  Nephrol Dial Transplant       Date:  2012-12-09       Impact factor: 5.992

8.  Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis.

Authors:  A V Mulay; C van Walraven; G A Knoll
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

9.  Preemptive living-donor renal transplantation: outcome and clinical advantages.

Authors:  S W Yoo; O J Kwon; C M Kang
Journal:  Transplant Proc       Date:  2009 Jan-Feb       Impact factor: 1.066

10.  Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

Authors:  Claudio Pozzi; Simeone Andrulli; Lucia Del Vecchio; Patrizia Melis; Giovanni B Fogazzi; Paolo Altieri; Claudio Ponticelli; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

View more
  9 in total

1.  Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study.

Authors:  Cédric Jäger; Susanne Stampf; Michael Koller; Min Jeong Kim; Karen Molyneux; Jonathan Barratt; Déla Golshayan; Karine Hadaya; Uyen Huynh-Do; Francoise-Isabelle Binet; Thomas F Mueller
Journal:  BMC Nephrol       Date:  2022-05-10       Impact factor: 2.585

2.  UNOS/OPTN Data-guided Assessment of Focal Segmental Glomerulosclerosis After Kidney Transplantation and Evaluation of Immunosuppressive Protocols in a Steroid-free Center.

Authors:  Sunil M Kurian; Samantha R Spierling Bagsic; Jamie Case; Bethany L Barrick; Randolph Schaffer; James C Rice; Christopher L Marsh
Journal:  Transplant Direct       Date:  2021-08-05

Review 3.  Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation.

Authors:  Gabriella Moroni; Mirco Belingheri; Giulia Frontini; Francesco Tamborini; Piergiorgio Messa
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 4.  Recurrent and de novo Glomerulonephritis After Kidney Transplantation.

Authors:  Wai H Lim; Meena Shingde; Germaine Wong
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

5.  Modifiable Variables Are Major Risk Factors for Posttransplant Diabetes Mellitus in a Time-Dependent Manner in Kidney Transplant: An Observational Cohort Study.

Authors:  Débora Dias de Lucena; João Roberto de Sá; José O Medina-Pestana; Érika Bevilaqua Rangel
Journal:  J Diabetes Res       Date:  2020-03-18       Impact factor: 4.011

6.  Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.

Authors:  Yan Hu; Minghua Shang; Yingfeng Shi; Min Tao; Weijie Yuan; Lunxian Tang; Xiaoyan Ma; Binbin Cui; Hui Chen; Xun Zhou; Shougang Zhuang; Na Liu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 7.  Diabetes and Cardiovascular Risk in Renal Transplant Patients.

Authors:  Jacek Rysz; Beata Franczyk; Maciej Radek; Aleksandra Ciałkowska-Rysz; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

8.  Recurrence of IgA Nephropathy after Kidney Transplantation in Adults.

Authors:  Audrey Uffing; Maria José Pérez-Saéz; Thomas Jouve; Mathilde Bugnazet; Paolo Malvezzi; Saif A Muhsin; Marie-Camille Lafargue; Roman Reindl-Schwaighofer; Alina Morlock; Rainer Oberbauer; Anna Buxeda; Carla Burballa; Julio Pascual; Seraina von Moos; Harald Seeger; Gaetano La Manna; Giorgia Comai; Claudia Bini; Luis Sanchez Russo; Samira Farouk; Pitchaphon Nissaisorakarn; Het Patel; Nikhil Agrawal; Gianna Mastroianni-Kirsztajn; Juliana Mansur; Hélio Tedesco-Silva; Carlucci Gualberto Ventura; Fabiana Agena; Elias David-Neto; Enver Akalin; Omar Alani; Marilda Mazzali; Roberto Ceratti Manfro; Andrea Carla Bauer; Aileen X Wang; Xingxing S Cheng; Jesse D Schold; Stefan P Berger; Paolo Cravedi; Leonardo V Riella
Journal:  Clin J Am Soc Nephrol       Date:  2021-08       Impact factor: 10.614

Review 9.  Primary IgA nephropathy: current challenges and future prospects.

Authors:  Rose S Penfold; Maria Prendecki; Stephen McAdoo; Frederick Wk Tam
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.